<DOC>
	<DOC>NCT02069132</DOC>
	<brief_summary>The purpose of this study is to validate the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm in a prospective cohort of elderly people (65 years or older) with heart valves and/or nonvalvular atrial fibrillation (AF) and at least one comorbid condition, and to assess the algorithm's prognostic relevance.</brief_summary>
	<brief_title>Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age â‰¥ 65 years Patients who initiate warfarin because of non valvular atrial fibrillation or heart valve replacement At least one comorbid condition At least two other drugs regularly assumed over and above warfarin Presence of systemic coagulopathies Presence of malignancies needing chemotherapy Inability or refusal to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Warfarin</keyword>
	<keyword>International Warfarin Pharmacogenetics Consortium algorithm</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Heart Valve Prosthesis Implantation</keyword>
	<keyword>elderly</keyword>
	<keyword>comorbidity</keyword>
</DOC>